SG11202105279SA - Methods of treating myeloproliferative disorders - Google Patents
Methods of treating myeloproliferative disordersInfo
- Publication number
- SG11202105279SA SG11202105279SA SG11202105279SA SG11202105279SA SG11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- myeloproliferative disorders
- treating myeloproliferative
- treating
- disorders
- Prior art date
Links
- 208000014767 Myeloproliferative disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/062534 WO2020112086A1 (en) | 2018-11-27 | 2018-11-27 | Methods of treating myeloproliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105279SA true SG11202105279SA (en) | 2021-06-29 |
Family
ID=64734125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105279SA SG11202105279SA (en) | 2018-11-27 | 2018-11-27 | Methods of treating myeloproliferative disorders |
Country Status (8)
| Country | Link |
|---|---|
| JP (2) | JP7453230B2 (https=) |
| KR (2) | KR102738936B1 (https=) |
| AU (1) | AU2018451360B2 (https=) |
| BR (1) | BR112021010134A2 (https=) |
| CA (1) | CA3120973A1 (https=) |
| EA (1) | EA202191489A1 (https=) |
| SG (1) | SG11202105279SA (https=) |
| WO (1) | WO2020112086A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021006205A (es) | 2018-11-27 | 2021-10-13 | Constellation Pharmaceuticals Inc | Metodos de tratamiento de trastornos mieloproliferativos. |
| EA202191489A1 (ru) * | 2018-11-27 | 2021-09-10 | Констеллейшен Фармасьютикалс, Инк. | Способы лечения миелопролиферативных расстройств |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| IL300337A (en) * | 2020-08-04 | 2023-04-01 | Constellation Pharmaceuticals Inc | 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[5,4-E]azepin-4-yl)acetamide for the treatment of thrombocythemia |
| WO2025155120A1 (ko) | 2024-01-18 | 2025-07-24 | 주식회사 엘지에너지솔루션 | 전극조립체, 이차 전지 및 배터리 유닛 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| CA2952830C (en) | 2014-06-20 | 2022-11-01 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
| EA202191489A1 (ru) * | 2018-11-27 | 2021-09-10 | Констеллейшен Фармасьютикалс, Инк. | Способы лечения миелопролиферативных расстройств |
-
2018
- 2018-11-27 EA EA202191489A patent/EA202191489A1/ru unknown
- 2018-11-27 SG SG11202105279SA patent/SG11202105279SA/en unknown
- 2018-11-27 BR BR112021010134-9A patent/BR112021010134A2/pt not_active Application Discontinuation
- 2018-11-27 KR KR1020217019508A patent/KR102738936B1/ko active Active
- 2018-11-27 KR KR1020247040010A patent/KR20250004357A/ko active Pending
- 2018-11-27 JP JP2021530108A patent/JP7453230B2/ja active Active
- 2018-11-27 CA CA3120973A patent/CA3120973A1/en active Pending
- 2018-11-27 WO PCT/US2018/062534 patent/WO2020112086A1/en not_active Ceased
- 2018-11-27 AU AU2018451360A patent/AU2018451360B2/en active Active
-
2024
- 2024-03-07 JP JP2024034717A patent/JP2024063214A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020112086A1 (en) | 2020-06-04 |
| KR20250004357A (ko) | 2025-01-07 |
| AU2018451360A1 (en) | 2021-06-10 |
| JP2024063214A (ja) | 2024-05-10 |
| CA3120973A1 (en) | 2020-06-04 |
| KR102738936B1 (ko) | 2024-12-06 |
| EA202191489A1 (ru) | 2021-09-10 |
| AU2018451360B2 (en) | 2022-05-26 |
| JP2022519425A (ja) | 2022-03-24 |
| KR20210095904A (ko) | 2021-08-03 |
| BR112021010134A2 (pt) | 2021-08-24 |
| JP7453230B2 (ja) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
| ZA202006746B (en) | Methods of treatment | |
| IL273693A (en) | Treatment of inflammatory disorders | |
| IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| IL267229A (en) | Methods of treating ocular disorders | |
| IL267818A (en) | Methods for treating neurological disorders | |
| SG11202103019WA (en) | Methods of treating myeloproliferative disorders | |
| SG11202105279SA (en) | Methods of treating myeloproliferative disorders | |
| IL269082A (en) | Methods for treating lysosomal disorders | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| IL275654A (en) | Methods of treating CASTOR-related disorders | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| IL269604A (en) | Pentides for the treatment of autoimmune diseases | |
| IL290983A (en) | Treatment methods | |
| LT3458067T (lt) | Neurologinių sutrikimų gydymas | |
| SG11202102982QA (en) | Methods of treating myeloproliferative disorders | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| ZA202002910B (en) | Treatment of skin disorders | |
| GB201918853D0 (en) | Methods of treatment | |
| PL3654965T3 (pl) | Sposoby leczenia autoimmunologicznych chorób mikronaczyniowych | |
| HK40055553A (zh) | 治疗骨髓增生性病症的方法 | |
| HK40052689A (en) | Methods of treating myeloproliferative disorders | |
| GB201604359D0 (en) | Treatment of tissue disorders | |
| IL268504A (en) | Methods of treating seizure disorders |